What is ImmuneID?
Operating at the intersection of precision medicine and immunology, ImmuneID is dedicated to the discovery and development of novel therapeutics designed to address complex medical challenges. The company utilizes a sophisticated platform to map immune responses, providing a foundation for targeted interventions that could redefine standard-of-care protocols. With its headquarters in the vibrant Cambridge, MA biotech hub, ImmuneID benefits from proximity to world-class research institutions and a dense network of life sciences talent, allowing it to maintain a competitive edge in the high-stakes field of drug discovery and precision immunology.
How much funding has ImmuneID raised?
ImmuneID has raised a total of $67M across 2 funding rounds:
Unspecified
$17M
Series A
$50M
Unspecified (2021): $17M with participation from Pitango HealthTech, In-Q-Tel, Xfund, and ARCH Venture Partners
Series A (2021): $50M led by In-Q-Tel, Pitango HealthTech, Alta Partners, Alexandria Venture Investments, Xfund, Section 32, Tekla Capital Management, ARCH Venture Partners, Redwood Capital Investments, and Longwood Fund
Key Investors in ImmuneID
In-Q-Tel
In-Q-Tel (IQT) is a not-for-profit strategic investment firm that acts as the U.S. national security community's venture arm, identifying and investing in early-stage commercial technology companies worldwide to deliver capabilities in areas like biotech and AI.
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists to commercialize innovations from research institutions.
Xfund
Xfund is an early-stage venture capital firm that supports entrepreneurs who think laterally and experiment across various disciplines, focusing on transformative technology emerging from academic research.
What's next for ImmuneID?
With the recent capital injection, ImmuneID is poised to scale its operational capacity and advance its lead candidates through the rigorous phases of clinical development. The strategic focus will likely center on expanding its proprietary platform capabilities and strengthening its intellectual property portfolio. As the company moves into this next phase of growth, the emphasis will remain on translating scientific breakthroughs into tangible patient outcomes, while simultaneously navigating the regulatory and commercial hurdles inherent in the biotech sector. The continued support from its diverse investor base provides the necessary runway to achieve these milestones and solidify its market position as a leader in the next generation of immune-focused therapeutics.
See full ImmuneID company page
